C4 Therapeutics, Inc. Payments for Repurchase of Initial Public Offering
C4 Therapeutics, Inc. (CCCC) reported Payments for Repurchase of Initial Public Offering of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2023-02-23
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-12-31 was $0.00.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2022-09-30 was $0.00.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for the quarter ending 2021-09-30 was $0.00.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2021 was $286.00K, a 92.07% decline from fiscal 2020.
- C4 Therapeutics, Inc. payments for repurchase of initial public offering for fiscal 2020 was $3.61M.
| Period end | Payments for Repurchase of Initial Public Offering 3 month | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 9 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | $0.00 10-K · filed 2023-02-23 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $0.00 derived: sum of 2 quarters · filed 2023-02-23 | -$28.00K derived: sum of 3 quarters · filed 2023-02-23 | $286.00K 10-K · filed 2023-02-23 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$28.00K derived: sum of 2 quarters · filed 2022-11-03 | $286.00K 10-Q · filed 2022-11-03 | $1.45M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $286.00K 10-Q · filed 2022-08-04 | $1.45M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | $314.00K 10-Q · filed 2022-05-05 | $1.47M derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $3.61M 10-K · filed 2022-02-24 | ||
| 2020-09-30 | $2.45M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |